Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369562 | 0.82 | KDM4E (0.58) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL23460209 | 0.81 | KDM4E (0.57) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL163725 | 0.81 | KDM4E (0.57) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL3230676 | 0.81 | KDM4E (0.57) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL15939996 | 0.80 | KDM4E (0.51) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL10732632 | 0.79 | KDM4E (0.55) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL2959778 | 0.79 | KDM4E (0.55) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL14975744 | 0.79 | PRKCZ (0.68) | KDM4EKMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL1760863 | 0.78 | MAPT (0.43) | KDM4EKMT2AMAPTHSD17B10ATM | |
| SCHEMBL1972551 | 0.78 | PRKCZ (0.44) | KDM4EKMT2AMAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528934-A | 2-Pyridothiophene compound, preparation method, application and antitubercular drug thereof | 桂林医学院 | 2025-02-28 | — | — | CN | claimed |
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-08-19 | — | — | US | disclosed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| CN-119528934-A | 2-Pyridothiophene compound, preparation method, application and antitubercular drug thereof | 桂林医学院 | 2025-02-28 | — | — | CN | disclosed |
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| CN-118852196-A | CYP11B2 inhibitor compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4426702-A1 | CONDENSED-PYRAZINE AMINE DERIVATIVES FOR TREATING SCA3 | Skyhawk Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2016-07-28 | — | — | US | disclosed |
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2708540-A1 | PYRIMIDO-DIAZEPINONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | disclosed |
| EP-0982992-A1 | FUNGICIDES | AgrEvo UK Limited (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998049899-A1 | FUNGICIDES | AGREVO UK LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | PIK3CA, WEE1, TKFC | KDM4E 3330/4885KMT2A 3684/4885MAPT 2216/4885 |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | KDM4E 3676/4885KMT2A 3059/4885MAPT 3190/4885 |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | REN, AGTR1, KCNJ1 | KDM4E 2816/4885KMT2A 1479/4885MAPT 4569/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | KDM4E 2301/4885KMT2A 2237/4885MAPT 863/4885 |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | KDM4E 4245/4885KMT2A 3974/4885MAPT 4092/4885 |
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | KDM4E 4245/4885KMT2A 3974/4885MAPT 4092/4885 |
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | KDM4E 3676/4885KMT2A 3059/4885MAPT 3190/4885 |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | BRAF, NRAS, TP53 | KDM4E 1153/4885KMT2A 2637/4885MAPT 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.